Immunogenicity and Safety Analysis of Inactivated Virus Vaccine against SARS-CoV-2: A Systematic Review of Phase 1/2 Clinical Trials

Main Article Content

Muhammad Mikail Athif Zhafir Asyura
Angelina Patricia Chandra


Introduction: The lingering Severe Acute Respiratory System-Coronavirus-2 (SARS-CoV-2) pandemic worldwide has called scientists to accelerate vaccine production and reduce the spread of the virus. The inactivated virus vaccine has been administered widely due to its potency. Following its recent public use, we aim to summarize the efficacy and safety of the inactivated vaccine, especially following Indonesia’s settlement on the SinoVac vaccine.

Materials and Methods: A systematic review was performed, searching for randomized controlled trials, according to the PRISMA statement throughout four online databases with studies published up to 2 February 2021. Critical appraisal was further conducted utilizing the Cochrane Risk of Bias Tool 2.0.

Results and Discussions: The search yielded six phase ½ clinical trials with a total of 3251 subjects. The outcome was obtained in seroconversion rates (%) after two doses of vaccine. Four studies administered the CoronaVac inactivated vaccine and resulted in a high seroconversion rate, ranging from 89—90%. The other two studies administered the BBV152 and BBIBP-CorV inactivated vaccine and showed similar results. Furthermore, a dose dependent relation is shown with higher doses showing higher seroconversion rates. The safety analysis reported injection site pain as an insignificant but most prevalent local adverse reaction, with other adverse reactions being mild to moderate respiratory tract infections

Conclusion: The inactivated vaccine’s efficacy has been proven to stimulate antibody response regardless of dosage, period of administration, and age, with insignificant adverse effects. Further phase 3 clinical trials and widespread administration with the help of non-governmental and medical student organizations are recommended

Article Details

How to Cite
Asyura, M. M. A. Z., Chandra, A. P. ., Agussalim, A. and Soloan, G. (2021) “Immunogenicity and Safety Analysis of Inactivated Virus Vaccine against SARS-CoV-2: A Systematic Review of Phase 1/2 Clinical Trials”, Journal of Asian Medical Students’ Association. Kuala Lumpur, Malaysia, 9(1). doi: 10.52629/jamsa.v9i1.258.
Systematic Reviews


WHO. WHOcoronavirus disease (COVID-19) dashboard [Internet]. Geneva: World Health Organization; date unknown [updated 2021 Feb 16]. Available from:

WHO. Draft landscape and tracker of COVID-19 candidate vaccines [Internet]. Geneva: World Health Organization; 2021 Feb 16. Available from:

RCN. The nurse who gave world’s first COVID-19 vaccine [Internet]. London: Royal College of Nursing; 2020 Dec 24. Available from:

Oxford. Number of people fully vaccinated against COVID-19 [Internet]. Oxford: University of Oxford; date unknown. Available from:

Nunnally BK, Turula VE, Sitrin RD. Vaccine analysis: strategies, principles, and control. 1st ed. Heidelberg: Springer; 2015; p1-665.

Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, Gao H. Development of an inactivated vaccine candidate for SARS-CoV-2. Science [Internet]. 2020 Jul 3 ;369(6499):77-81. Available from:

Cochrane. RoB 2: A revised Cochrane risk-of-bias tool for randomized trials [Internet]. London: Cochrane; date unknown . Available from:

Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, Yang Y. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. Jama [Internet]. 2020 Sep 8;324(10):951-60. Available from:

Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W, Chen X. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases [Internet]. 2020 Nov 17; 21(2):181-192. Available from:

Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, Ganneru B, Sapkal G, Yadav P, Abraham P, Panda S. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. The Lancet Infectious Diseases [Internet]. 2021 Jan 21. Available from:

Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, Huang W. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. The Lancet Infectious Diseases [Internet]. 2021 Jan; 21(1):39-51. Available from:

Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, Li M, Jin H, Cui G, Chen P, Wang L. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. The Lancet Infectious Diseases [Internet]. 2021 Feb 3. Available from:

Che Y, Liu X, Pu Y, Zhou M, Zhao Z, Jiang R, Yin Z, Xu M, Yin Q, Wang J, Pu J. Randomized, double-blinded and placebo-controlled phase II trial of an inactivated SARS-CoV-2 vaccine in healthy adults. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America [Internet]. 2020 Nov. Available from:

Pradhan D, Biswasroy P, Ghosh G, Rath G. A review of current interventions for COVID-19 prevention. Archives of Medical Research [Internet]. 2020 Apr 30; 51(5):363-74. Available from:

Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus Research [Internet]. 2020 Aug 13; 198114. Available from:

Shrestha N, Shad MY, Ulvi O, Khan MH, Karamehic-Muratovic A, Nguyen US, Baghbanzadeh M, Wardrup R, Aghamohammadi N, Cervantes D, Nahiduzzaman KM. The impact of COVID-19 on globalization. One Health [Internet]. 2020 Oct;100180. Available from:

Suryahadi A, Al Izzati R, Suryadarma D. The impact of COVID-19 outbreak on poverty: An estimation for Indonesia. The SMERU Research Institute [Internet]. 2020 Apr. Available from:,lead%20to%20a%20global%20recession.&text=The%20economic%20impact%20is%20also,between%201%20and%204%20percent.

Papageorghiou AT. The new normal. International Journal of Obstetrics and Gynaecology [Internet]. 2020 May 14; 127(7): 779–780. Available from:

Ophinni Y, Hasibuan AS, Widhani A, Maria S, Koesnoe S, Yunihastuti E, Karjadi TH, Rengganis I, Djauzi S. COVID-19 vaccines: current status and implication for use in indonesia. Acta Medica Indonesiana [Internet]. 2020 Dec 28; 52(4):388. Available from:

Raja AT, Alshamsan A, Al-Jedai A. Status of the current COVID-19 vaccine candidates: implications in the saudi population. Saudi Pharmaceutical Journal [Internet]. 2020 Nov 10. Available from:

Bartsch SM, O'Shea KJ, Wedlock PT, Strych U, Ferguson MC, Bottazzi ME, Randall SL, Siegmund SS, Cox SN, Hotez PJ, Lee BY. The Benefits of vaccinating with the first available COVID-19 coronavirus vaccine. American Journal of Preventive Medicine [Internet]. 2021 Jan 19. Available from:

CDC. Reinfection with COVID-19 [Internet]. Atlanta: Center for Disease Control and Prevention; date unknown [updated 2020 Oct 27]. Available from:

Burrell CJ, Howard CR, Murphy FA. Fenner and White's Medical Virology. Academic Press; 2016 Nov 9.

Delrue I, Verzele D, Madder A, Nauwynck HJ. Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges. Expert Review of Vaccines [Internet]. 2012 Jun 1; 11(6):695-719. Available from:

Sridhar S, Brokstad KA, Cox RJ. Influenza vaccination strategies: comparing inactivated and live attenuated influenza vaccines. Vaccines [Internet]. 2015; 3(2):373-89. Available from:

Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, Xu W, Zhao Y, Li N, Zhang J, Liang H. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell [Internet]. 2020 Aug 6;182(3):713-21. Available from:

Stuurman AL, Marano C, Bunge EM, De Moerlooze L, Shouval D. Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines–A systematic review. Human Vaccines & Immunotherapeutics [Internet]. 2017 Mar; 13(3):724-36. Available from:

Islam MT, Chowdhury F, Qadri F, Sur D, Ganguly NK. Trials of the killed oral cholera vaccine (Shanchol) in India and Bangladesh: Lessons learned and way forward. Vaccine [Internet]. 2020 Feb 29; 38:A127-31. Available from:

Lopez AL, Deen J, Azman AS, Luquero FJ, Kanungo S, Dutta S, Von Seidlein L, Sack DA. Immunogenicity and protection from a single dose of internationally available killed oral cholera vaccine: a systematic review and metaanalysis. Clinical Infectious Diseases [Internet]. 2018 Jun 1; 66(12):1960-71. Available from:

Jiang S, Hillyer C, Du L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends in Immunology [Internet]. 2020 May 1; 41(5):355-9. Available from:

Yuan P, Ai P, Liu Y, Ai Z, Wang Y, Cao W, Xia X, Zheng JC. Safety, Tolerability, and immunogenicity of COVID-19 vaccines: A systematic review and meta-analysis [Internet]. 2020 Nov 4. Available from:

Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. British Journal of Cancer [Internet]. 2014 Feb; 110(3):551-5. Available from: